Page last updated: 2024-12-06

pefloxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pefloxacin is a synthetic fluoroquinolone antibiotic that inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. It has a broad spectrum of activity against gram-negative and gram-positive bacteria. Pefloxacin was initially studied for its potential treatment of urinary tract infections, respiratory infections, and other bacterial infections. However, its use has declined due to concerns about potential adverse effects, such as tendonitis and tendon rupture. It is still used in some parts of the world, but its use is generally restricted to cases where other antibiotics are ineffective or contraindicated.'

Pefloxacin: A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pefloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6 and 7 by ethyl, carboxy, fluorine, and 4-methylpiperazin-1-yl groups, respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID51081
CHEMBL ID267648
CHEBI ID50199
SCHEMBL ID34292
MeSH IDM0023653

Synonyms (98)

Synonym
1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
pefloxacinum [inn-latin]
3-quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo
3-quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-
einecs 274-611-8
1584rb
brn 0567618
am-725
3-quinolinecarboxylic acid, 1,4-dihydro-1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-
pefloxacin [inn-french]
pefloxacino [inn-spanish]
1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-methyl-1-piperazinyl)-3-quinolinecarboxylic acid
AB00600922-14
BRD-K55034111-066-02-3
eu 5306
MLS000713556
smr000273037
OPREA1_546341
perfloxacin
1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
pefloxacino
CHEBI:50199 ,
pefloxacinum
labocton
1589 rb
eu-5306
pefloxacin
1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1- piperazinyl)-4-oxo-3-quinolinecarboxylic acid
OPREA1_063677
BSPBIO_003571
BAS 00463355
DB00487
pefloxacine
pflx
pefloxacin (usan/inn)
70458-92-3
D02306
STK169677
KBIO3_002945
SPBIO_000127
SPECTRUM2_000034
SPECTRUM3_001971
HMS2090H09
AKOS000280245
1589-rb
CHEMBL267648
HMS1613E05
1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
1-ethyl-6-fluoro-7-(4-methylpiperazin-4-ium-1-yl)-4-oxoquinoline-3-carboxylate
1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
BBL008795
ccris 8210
unii-2h52z9f2q5
2h52z9f2q5 ,
pefloxacin [usan:inn:ban]
CCG-111464
FT-0630798
NCGC00177986-04
F5577-0091
pefloxacin [mi]
pefloxacin [usan]
pefloxacin [who-dd]
pefloxacin [inn]
AB00600922-12
HY-B0147
CS-1961
SCHEMBL34292
P-1198
pefloxacin, antibiotic for culture media use only
DTXSID3048493
FHFYDNQZQSQIAI-UHFFFAOYSA-N
1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-methylpiperazinyl)quinoline-3-carboxylic acid
MLS006011797
1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid;methanesulfonic acid
bdbm57936
1-ethyl-6-fluoro-4-keto-7-(4-methylpiperazino)quinoline-3-carboxylic acid;mesylic acid
cid_119525
1-ethyl-6-fluoranyl-7-(4-methylpiperazin-1-yl)-4-oxidanylidene-quinoline-3-carboxylic acid;methanesulfonic acid
AB00600922_15
AB00600922_16
SR-01000356843-6
VU0243371-6
mfcd00865015
sr-01000356843
SR-01000356843-1
SBI-0206758.P001
HMS3713G04
BCP20511
1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylicacid
VS-01991
pefloxacin,(s)
Q2601859
pefloxacinium
BRD-K55034111-001-02-0
BRD-K55034111-066-07-2
3-quinolinecarboxylic acid,1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-
EN300-18563416
gtpl12411

Research Excerpts

Overview

Pefloxacin is an antibacterial agent belonging to the group of quinolones having a methyl-carboxylic acid which possesses a high activity.

ExcerptReferenceRelevance
"Pefloxacin (PFLX) is an antibiotic, which shows broad spectrum antimicrobial activities. "( Under ambient UVA exposure, pefloxacin exhibits both immunomodulatory and genotoxic effects via multiple mechanisms.
Chandra, S; Chopra, D; Dubey, D; Dwivedi, A; Mandal, P; Ray, RS; Singh, J; Srivastva, AK; Tripathi, A, 2018
)
2.22
"Pefloxacin is a second-generation fluoroquinolone antibiotic. "( Pefloxacin induced changes in serotonergic innervation and mast cell number in rat salivary glands.
Bácskai, T; Deák, Á; Kelentey, B; Matesz, C; Skopkó, BE, 2020
)
3.44
"Pefloxacin is a new kind of antibiotic. "( [Study on fluorescence method of pefloxacin].
Chen, L; Huang, S; Ma, L, 1997
)
2.02
"Pefloxacin mesylate is a flouroquinolone antibacterial drug effective in the treatment of bacterial conjunctivitis. "( Ocular inserts for controlled delivery of pefloxacin mesylate: preparation and evaluation.
Ali, A; Aqil, M; Sultana, Y, 2005
)
2.04
"Pefloxacin is a new methyl-4-piperazinyl quinolone. "( In vitro activity of pefloxacin compared to that of quinolones and other antimicrobial agents.
Chin, NX; Labthavikul, P; Neu, HC; Saha, G, 1984
)
2.03
"Pefloxacin is a new quinolone with significant in vitro antibacterial activity and a broad spectrum. "( [Pefloxacine: diffusion into bronchial mucus].
Benard, Y; Langeard, M; Morel, C; Vergnaud, M, 1984
)
2.62
"Pefloxacin is a fluoroquinolone which is commonly used in systemic infections."( Carrier-mediated system for pefloxacin uptake in human monocytes.
Mémin, E; Panteix, G; Revol, A, 1997
)
1.31
"Pefloxacin mesylate is a broad spectrum fluoroquinolone active against pathogens with multiple resistance. "( [Pefloxacin mesylate--clinical effectiveness in various forms of infectious-inflammatory diseases].
Bakalova, LA; Blatun, LA; Fedorov, SM; Iakovlev, VP; Koshil', OI; Kurmanova, KB; Nestetrova, LIa; Pozdniakova, VP; Smirnova, LB; Strachunskiĭ, LS, 1997
)
2.65
"Pefloxacin is a fluorinated quinolone with good in-vitro activity against these pathogens."( Oral pefloxacin in the treatment of CAPD peritonitis.
Chua, CT; Kon, SP; Ngeow, NF; Tan, HW, 1992
)
1.52
"Pefloxacin is an antibacterial agent belonging to the group of quinolones having a methyl-carboxylic acid which possesses a high activity as compared to other quinolonic drugs. "( [Pefloxacin in the treatment of lower respiratory tract infections].
Bianco, A; Cuccurullo, S; Dericoloso, A; Micillo, E; Moro, RA; Tranchese, D,
)
2.48
"Pefloxacin is a valuable drug for use in bacteriologically proven sensitive infections and combination with aminoglycosides or beta-lactam agents should prevent the development of resistance."( Pefloxacin therapy for nosocomial infections in the intensive care unit.
Potgieter, PD, 1990
)
2.44
"Pefloxacin is a fluorinated quinolone that is structurally related to nalidixic acid. "( Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Gonzalez, JP; Henwood, JM, 1989
)
3.16
"Pefloxacin is a safe and effective agent for therapy of typhoid fever."( Clinical experience with pefloxacin in the therapy of typhoid fever.
Altucci, P; Briante, V; Cristiano, P; Iovene, MR; Morelli, G; Simioli, F,
)
1.16
"Pefloxacin is a novel quinolone whose antibacterial spectrum and bactericidal activity allow it to be considered for use in the treatment of orchitis and epididymitis Prior to clinical study the authors investigated the degree of epididymal diffusion of Pefloxacin."( [Acute epididymitis and antibiotherapy. Measurement of the epididymal diffusion of pefloxacin].
Costa, P; Favier, M; Galtier, M; Grasset, D; Hansel, S; Laurelli, JM; Louis, JF; Navratil, H; Nivard, G, 1989
)
1.22
"Pefloxacin (Pef) is a new quinolone which has been shown to have good in-vitro activity against Staphylococcus aureus, and to reach high tissue concentrations. "( Comparative efficacy of pefloxacin and six other antimicrobial agents on Staphylococcus aureus experimental abscesses.
Bouanchaud, DH; Huet, Y; Rolin, O, 1986
)
2.02
"Pefloxacin is a new quinolone carboxylic acid with a broad spectrum of antibacterial activity. "( In-vitro activity of pefloxacin compared to other antibiotics.
Crokaert, F; Glupczynski, Y; Van der Linden, MP; Yourassowsky, E, 1986
)
2.03
"Pefloxacin was shown to be an effective and safe therapy for lower respiratory tract infections contracted in hospital in elderly patients."( Pefloxacin in the treatment of lower respiratory tract infections in geriatrics.
Vanderdonckt, J,
)
2.3
"Oral pefloxacin would seem to be a convenient and useful treatment of spontaneous, gram-negative, bacterial peritonitis in cirrhosis."( Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis.
Beauchant, M; Becq-Giraudon, B; Bouquet, S; Breux, JP; Cardey, J; Fourtillan, JP; Silvain, C, 1987
)
0.98
"Pefloxacin is a potentially useful antistaphylococcal agent."( In vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphylococcal drugs.
Fass, RJ; Helsel, VL, 1987
)
1.26

Effects

Pefloxacin has been increasingly used in veterinary medicine to treat microbial infections. It has a broad spectrum of activity against a great number of Gram-negative and Gram-positive bacteria. Pefl Oxacin was compared to cotrimoxazole in the treatment of typhoid fever in adults.

ExcerptReferenceRelevance
"Pefloxacin has a broad spectrum of activity against a great number of Gram-negative and Gram-positive bacteria. "( Pefloxacin clinical pharmacokinetics.
Bressolle, F; Galtier, M; Gonçalves, F; Gouby, A, 1994
)
3.17
"Pefloxacin has been increasingly used in veterinary medicine to treat microbial infections. "( Preparation of anti-pefloxacin antibody and development of an indirect competitive enzyme-linked immunosorbent assay for detection of pefloxacin residue in chicken liver.
Liu, J; Liu, W; Lu, S; Xi, R; Zhang, Y; Zhao, C, 2006
)
2.1
"Pefloxacin has been shown to have good intraocular penetration when given systemically. "( Tolerability, kinetics, and efficacy of subconjunctival pefloxacin in pigmented rabbits.
Cochereau, I; D'Hermies, F; Marrakchi-Benjaafar, S; Pocidalo, JJ, 1995
)
1.98
"Pefloxacin has a broad spectrum of activity against a great number of Gram-negative and Gram-positive bacteria. "( Pefloxacin clinical pharmacokinetics.
Bressolle, F; Galtier, M; Gonçalves, F; Gouby, A, 1994
)
3.17
"Pefloxacin has been shown to have good intraocular penetration when given systemically."( Kinetics and tolerability of intravitreal pefloxacin in rabbits.
Bauchet, J; Cochereau-Massin, I; D'Hermies, F; Faurisson, F; Marrakchi-Benjaafar, S; Pocidalo, JJ; Vallois, JM, 1994
)
1.27
"Pefloxacin has been in clinical use in France since 1985. "( Pefloxacin: safety in man.
Guyot, A; Simon, J, 1990
)
3.16
"Pefloxacin has achieved a greater than 70% clinical cure rate and a microbiological response of over 80% in cases of nosocomial pneumonia in the ICU."( Pefloxacin therapy for nosocomial infections in the intensive care unit.
Potgieter, PD, 1990
)
2.44
"Pefloxacin, which has been shown to have a high in vitro activity against Salmonella spp., was compared to cotrimoxazole in the treatment of typhoid fever in adults. "( Prospective randomized comparative trial of pefloxacin versus cotrimoxazole in the treatment of typhoid fever in adults.
Benbachir, M; el Filali, KM; el Mdaghri, N; Hajji, M; Himmich, H, 1988
)
1.98
"Pefloxacin therefore has good penetration of heart valves and is present for up to 24 h."( Penetration of pefloxacin in human heart valves.
Brion, N; Lefevre, JJ; Lessana, A; Montay, G; Mosset, F, 1986
)
1.35

Actions

Pefloxacin demonstrated lower peak concentrations in the urine than norfloxacIn (mean, 217.2 mg/l versus 492.9 mg/L as determined by the microbiological assay) But pefloxAcin was present over a longer period of time in sufficient concentrations.

ExcerptReferenceRelevance
"Pefloxacin did not suppress the immunity."( [Effectiveness of pefloxacin in brucellosis].
Iudin, SM; Kkhamfyang, S; Kurmanova, KB, 1995
)
1.35
"Pefloxacin demonstrated lower peak concentrations in the urine than norfloxacin (mean, 217.2 mg/l versus 492.9 mg/l as determined by the microbiological assay) but pefloxacin was present over a longer period of time in sufficient concentrations than norfloxacin."( Urine bactericidal activity of pefloxacin versus norfloxacin in healthy female volunteers after a single 800-mg oral dose.
Hofbauer, H; Kinzig-Schippers, M; Kresken, M; Naber, KG; Reiz, A; Rustige-Wiedemann, C; Sörgel, F; Wiedemann, B,
)
1.14

Treatment

Pefloxacine treatment was at least partially effective in preventing further increase of proteinuria in rats with adriamycin nephropathy. Treatment with pefloxacin alone resulted in high SBAs against E.

ExcerptReferenceRelevance
"Pefloxacine treatment was at least partially effective in preventing further increase of proteinuria in rats with adriamycin nephropathy."( The influence of pefloxacine on experimental adriamycin-induced nephrotic syndrome in rats.
Merta, M; Nĕmecek, K; Poledne, R; Rychlík, I; Stípek, S; Tĕmínová, J; Tesar, V; Zima, T, 1996
)
1.35
"Pefloxacin treatment by itself did not alter proto-oncogene mRNA levels in the parotid gland."( Inhibition of rat parotid gland growth response induced by chronic isoproterenol following treatment with quinolone antibiotics.
Humphreys-Beher, MG; Kelentey, B; Kerr, M; Purushotham, KR; Tao, Z; Zelles, T, 1996
)
1.02
"Pefloxacin treatment for several days induced oxidative damage of type I collagen, with the alterations being identical to those observed in the experimental tendinous ischemia and reperfusion model."( Pefloxacin-induced achilles tendon toxicity in rodents: biochemical changes in proteoglycan synthesis and oxidative damage to collagen.
Gegout-Pottie, P; Gillet, P; Minn, A; Netter, P; Simonin, MA; Terlain, B, 2000
)
2.47
"Treatment with pefloxacin resulted in a normalization of the bone remodeling process and a significant reduction of angiogenic cytokines, with rapid and sustained improvement of symptoms, suggesting that these factors might be implicated in the pathophysiology of this syndrome."( Schnitzler's syndrome: increased levels of bone formation and angiogenesis factors are reduced after successful pefloxacin treatment.
Dimopopoulos, MA; Gavriatopoulopu, M; Kastritis, E; Katoulis, A; Panayiotides, I; Terpos, E, 2008
)
0.9
"Treatment with pefloxacin alone resulted in high SBAs against E."( Bactericidal activity and killing rate of serum from volunteers receiving pefloxacin alone or in combination with amikacin.
Husson, M; Klastersky, J; Lauzon, D; Lieppe, S; Lopez, AP; Van der Auwera, P, 1986
)
0.84

Toxicity

ExcerptReferenceRelevance
" During this period of time, the Rhone-Poulenc Drug Safety Department has received 213 spontaneous reports concerning patients who experienced a total of 316 adverse events."( Pefloxacin: safety in man.
Guyot, A; Simon, J, 1990
)
1.72
" No adverse effects were noticed during or after pefloxacin administration."( Efficacy and safety of pefloxacin in the treatment of severe infections in patients hospitalized in intensive care units.
Lauwers, S; Naessens, A; Pierard, D; Vincken, W, 1986
)
0.84
" First group (NA, OFX) showed greater intrinsic tenotoxicity for young adult than immature tenocytes, second group (PEF) was highly toxic for immature and young adult cells."( Age-dependent effects on redox status, oxidative stress, mitochondrial activity and toxicity induced by fluoroquinolones on primary cultures of rabbit tendon cells.
Debray, M; Dutot, M; Martin, C; Pouzaud, F; Rat, P; Warnet, JM, 2006
)
0.33

Pharmacokinetics

Pefloxacin coadministered with rifampicin reduced plasma and saliva elimination half-life. Peak plasma concentration, area under the concentration time curve, volume of distribution, minimum absorption time, absorption rate constant, and absorption half- life showed a significant increase.

ExcerptReferenceRelevance
" Two pharmacokinetic studies were performed for each quinolone, on days four and eight of the treatment."( Effects of ketoprofen (NSAID) on the pharmacokinetics of pefloxacin and ofloxacin in healthy volunteers.
Borsa-Lebas, F; Etienne, I; Fillastre, JP; Gy, C; Humbert, G; Leroy, A, 1992
)
0.53
"Bayesian estimation of individual pefloxacin pharmacokinetic parameters was evaluated in patients with renal (n = 34) or hepatic (n = 16) impairments who participated in experimental pharmacokinetic studies during pefloxacin development."( Evaluation of Bayesian estimation to discriminate subpopulations of patients with altered pharmacokinetics using fragmentary data: a pilot study with pefloxacin.
Bruno, R; Frydman, A; Gaillot, J; Iliadis, A; Le Roux, Y; Montay, G; Rosier, P, 1991
)
0.76
" The overall elimination half-life was 19."( Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Dombros, N; Nikolaidis, P; Oreopoulos, DG; Paton, TW; Tourkantonis, A; Walker, SE, 1991
)
0.66
"Ten patients with spontaneous ascitic fluid infections received intravenously 400 mg of pefloxacin for pharmacokinetic evaluation of the drug and its diffusion into peritoneal space."( [Clinical and pharmacokinetic study of pefloxacin in spontaneous ascitic fluid infections].
Andrejak, M; Baillet, J; Ducroix, JP; Eb, F; Hary, L; Smail, A; Tondriaux, A,
)
0.62
"The pharmacokinetic properties of the new fluoroquinolones are characterized by a high volume of distribution, long biological half-life, low serum protein binding, elimination by renal and extrarenal mechanisms with high total and renal clearances, limited biotransformation and moderate to excellent bioavailability after oral administration."( Quinolone pharmacokinetics and metabolism.
Boeckk, M; Borner, K; Deppermann, N; Höffken, G; Koeppe, P; Lode, H, 1990
)
0.28
" For the other new quinolones, a decrease in glomerular filtration rate below 20-30 ml/min induces an increase in terminal half-life and a decrease in plasma and renal clearance, related to the degree of renal impairment."( Pharmacokinetics of quinolones in renal insufficiency.
Borsa-Lebas, F; Dhib, M; Fillastre, JP; Humbert, G; Leroy, A; Moulin, B, 1990
)
0.28
"The principal pharmacokinetic values of pefloxacin, ofloxacin and ciprofloxacin were obtained from a review of the literature."( [Serum pharmacokinetics and in vitro antibacterial activity of pefloxacin, ofloxacin and ciprofloxacin].
Jarlier, V; Nordmann, P,
)
0.64
" The pharmacokinetic profile of pefloxacin is characterised by high bioavailability after oral administration, a long half-life and good penetration of tissue and body fluids."( Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Gonzalez, JP; Henwood, JM, 1989
)
2
" There were no significant differences in Tmax (0."( Comparative oral pharmacokinetics of fleroxacin and pefloxacin.
De Lepeleire, I; De Schepper, PJ; Tjandra-Maga, TB; Van Hecken, A; Verbesselt, R, 1988
)
0.53
" A dosing schedule for the quinolones was proposed on the basis of pharmacokinetic parameters and microbiologic activity."( Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
Andrews, JM; Griggs, D; Wise, R,
)
0.13
"The pharmacokinetic profile of pefloxacin is one of the major assets of this new antibiotic of the quinolone family."( [Pharmacokinetic behavior of pefloxacin in man].
Fourtillan, JB, 1986
)
0.85
" The mean elimination half-life was significantly increased in the patients (29."( Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis.
Beauchant, M; Becq-Giraudon, B; Bouquet, S; Breux, JP; Cardey, J; Fourtillan, JP; Silvain, C, 1987
)
0.52
"The pharmacokinetic properties of the new quinolones are characterised by a high volume of distribution, long biological half-life, low serum protein binding, elimination mainly by the kidneys, high total and renal clearances, limited biotransformation and a moderate to excellent bioavailability after oral administration."( Comparative pharmacokinetics of new quinolones.
Borner, K; Glatzel, P; Höffken, G; Koeppe, P; Lode, H; Olschewski, P; Prinzing, C; Reimnitz, D; Sievers, B; Wiley, R, 1987
)
0.27
" The mean serum elimination half-life was 11."( Pharmacokinetics and tissue penetration of orally administered pefloxacin.
Andrews, JM; Ashby, JP; McLeod, A; Webberley, JM; Wise, R, 1987
)
0.51
" The mean apparent elimination half-life was 13."( Pharmacokinetics of pefloxacin in renal insufficiency.
Bariety, J; Cunci, R; Jacquot, C; Montay, G, 1985
)
0.59
"A dose-dependent pharmacokinetic study of pefloxacin was performed after four intravenous infusions and four orally administered doses."( Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans.
Barre, J; Houin, G; Tillement, JP, 1984
)
0.8
" Pharmacokinetic parameters evaluated in patients on day 1 of treatment were compared with those computed in 11 healthy volunteers (the control group) after a single dose."( Multiple-dose pharmacokinetics of pefloxacin in patients with hepatocellular deficiency.
Bressolle, F; de la Coussaye, JE; Dubois, A; Eledjam, JJ; Galtier, M; Gény, F; Gomeni, R; Joubert, P; Raffanel, C; Saissi, G, 1993
)
0.57
" Doses of pefloxacin and concentrations in cerebrospinal fluid and plasma (total and unbound) at the pharmacodynamic endpoint were all independent of infusion rate, whereas only cerebrospinal fluid concentrations of norfloxacin were independent of infusion rate."( Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of pefloxacin and norfloxacin in rats.
Bouquet, S; Couet, W; Courtois, P; Delon, A; Huguet, F; Vierfond, JM, 1997
)
0.93
" This was calculated by dividing the area under the concentration curve (AUC) of pefloxacin in brain by its AUC in blood (k=AUC(brain)/AUC(blood))."( Pharmacokinetics of pefloxacin and its interaction with cyclosporin A, a P-glycoprotein modulator, in rat blood, brain and bile, using simultaneous microdialysis.
Tsai, TH, 2001
)
0.86
" Elimination half-life was estimated as 22."( Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery.
Calvo, B; Campo, E; Errasti, J; Gascón, AR; Hernández, RM; Olea, E; Pedraz, JL, 2002
)
0.56
"The aim of this study was to elucidate some of the pharmacokinetic parameters of pefloxacin in lactating goats (n = 5) following intravenous (i."( Some pharmacokinetic parameters of pefloxacin in lactating goats.
Abd El-Aty, AM; Goudah, A, 2002
)
0.82
"Fluoroquinolones present various pharmacokinetic properties."( [Pharmacokinetics and dose adaptation of ofloxacine, pefloxacine and ciprofloxacine during haemodialysis and continuous ambulatory peritoneal dialysis].
Christmann, D; Daniel, JP; Moulin, B, 2004
)
0.57
"If appropriately accounted for in a pharmacokinetic (PK)-pharmacodynamic (PD) model, time-varying covariates can provide additional information to that obtained from time-constant covariates."( Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.
Karlsson, MO; Milligan, PA; Thomson, AH; Wählby, U, 2004
)
0.32
" The apparent volume of distribution based on the total area under the plasma drug concentration curve [(Vd(area)] and the apparent volume of distribution based on the zero time plasma concentration intercept of the elimination phase [Vd(B)] were significantly higher in trikatu treated animals indicating a better penetration of the drug."( Effect of trikatu pretreatment on the pharmacokinetics of pefloxacin administered orally in mountain Gaddi goats.
Dama, MS; Dardi, MS; Katoch, VC; Varshneya, C, 2008
)
0.59
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"Therapeutic activity, pharmacokinetic and bioavailability on animals (inbred white mouse, rabbits) were evaluated for Ofloxacin-PhPO and Pefloxacin-genova in comparison with innovator products--Tarivid and Abaktal."( [Chemotherapy activity and pharmacokinetics of the fluoroquinolones generics Ofloxacin-PhPO and Pefloxacin-genova].
Bobrov, VI; Borisov, MM; Ptitsina, SN, 2007
)
0.76
"In the present study, the pharmacokinetic and drug interaction evaluation of two drugs pefloxacin and paracetamol was carried out by a single-dose, two-treatment and two-sequence crossover design."( Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan.
Ali, SA; Gauhar, S; Naqvi, SB; Shoaib, MH, 2014
)
0.87
" The obtained pharmacokinetic parameters suggested that PM reached peak levels in various tissues within 1-2 h after its oral administration, and was mainly concentrated in liver and kidney."( Pharmacokinetics and tissue distribution of pefloxacin mesylate in chickens.
Feng, M; Fu, J; Huang, Z; Li, G; Lin, S; Song, M; Wan, R; Wang, S; Yang, S; Zhao, Z, 2018
)
0.74

Compound-Compound Interactions

Penicillin V (500 mg twice a day) vs placebo given in combination with oral pefloxacin. Fosfomycin was found to be additive or moderately synergistic. Pefloxacins killed staphylococci more rapidly than oxacillin or vancomycin alone.

ExcerptReferenceRelevance
"The efficacies of the quinolones ciprofloxacin and pefloxacin alone and in combination with rifampin were compared with those of vancomycin alone and in combination with rifampin in a rat model of chronic osteomyelitis caused by methicillin-resistant Staphylococcus aureus."( Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis.
Dworkin, R; Kunz, S; Modin, G; Rich, R; Sande, M; Zak, O, 1990
)
0.8
"The in vitro activity of fosfomycin alone and in combination with rifampin, pefloxacin and imipenem was studied by the time-kill method against staphylococci."( In vitro activity of fosfomycin combined with rifampin, pefloxacin and imipenem against staphylococci: a study by the time-kill curve method.
Bebear, C; Lafferriere, C; Noury, P; Quentin, C; Saivin, S, 1987
)
0.75
" Pefloxacin combined with oxacillin or vancomycin killed staphylococci more rapidly than oxacillin or vancomycin alone but less rapidly than pefloxacin alone."( In vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphylococcal drugs.
Fass, RJ; Helsel, VL, 1987
)
1.45
" Fosfomycin combined with pefloxacin was found to be additive or moderately synergistic."( [In vitro action of fosfomycin combined with rifampicin, pefloxacin and imipenem on staphylococci (checkerboard method in a liquid medium)].
Bebear, C; Laurent, C; Noury, P; Quentin, C; Saivin, S, 1987
)
0.82
"The in vivo efficacy of ciprofloxacin or pefloxacin alone or in combination with fosfomycin was evaluated in experimental aortic valve endocarditis induced in 133 rabbits by a multidrug-susceptible or multidrug-resistant strain of Pseudomonas aeruginosa."( Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa.
Baron, D; Bugnon, D; Caillon, J; Drugeon, H; Jehl, F; Le Conte, P; Potel, G; Stephant, G; Xiong, YQ, 1995
)
0.82
"To determine the effect of oral penicillin V combined with a fluoroquinolone (pefloxacin) on the occurrence of fever and streptococcal and other gram-positive coccal bacteremic infections in granulocytopenic patients with cancer."( Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and
, 1994
)
0.72
"Penicillin V (500 mg twice a day) vs placebo given in combination with oral pefloxacin (400 mg twice a day)."( Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and
, 1994
)
0.72

Bioavailability

The results demonstrated that the carbopol/methyl cellulose mixture can be used as an in situ gelling vehicle to enhance the ocular bioavailability of pefloxacin mesylate. PefloxacIn coadministered with rifampicin reduced plasma and saliva elimination half-life.

ExcerptReferenceRelevance
" Relative to the IV dose the bioavailability following oral administration of pefloxacin was 76%."( Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Dombros, N; Nikolaidis, P; Oreopoulos, DG; Paton, TW; Tourkantonis, A; Walker, SE, 1991
)
0.89
"The pharmacokinetic properties of the new fluoroquinolones are characterized by a high volume of distribution, long biological half-life, low serum protein binding, elimination by renal and extrarenal mechanisms with high total and renal clearances, limited biotransformation and moderate to excellent bioavailability after oral administration."( Quinolone pharmacokinetics and metabolism.
Boeckk, M; Borner, K; Deppermann, N; Höffken, G; Koeppe, P; Lode, H, 1990
)
0.28
" The pharmacokinetic profile of pefloxacin is characterised by high bioavailability after oral administration, a long half-life and good penetration of tissue and body fluids."( Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Gonzalez, JP; Henwood, JM, 1989
)
2
" Out of the three quinolone compounds, only colon-coated pefloxacin was associated with a considerable absorption rate at colonic level."( Quinolones and colonization resistance in human volunteers.
Geitz, JN; Lerk, CF; Tarko-Smit, NJ; Van Saene, HK; Van Saene, JJ, 1986
)
0.52
" The bioavailability of pefloxacin was complete and plasma concentrations after iv or oral administration were similar."( Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers.
Djebbar, F; Fourtillan, JB; Frydman, AM; Gaillot, J; Le Roux, Y; Lefebvre, MA, 1986
)
0.9
"The pharmacokinetic properties of the new quinolones are characterised by a high volume of distribution, long biological half-life, low serum protein binding, elimination mainly by the kidneys, high total and renal clearances, limited biotransformation and a moderate to excellent bioavailability after oral administration."( Comparative pharmacokinetics of new quinolones.
Borner, K; Glatzel, P; Höffken, G; Koeppe, P; Lode, H; Olschewski, P; Prinzing, C; Reimnitz, D; Sievers, B; Wiley, R, 1987
)
0.27
"Pefloxacin mesylate is well absorbed by the oral route."( Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.
Goueffon, Y; Montay, G; Roquet, F, 1984
)
1.95
" The bioavailability of the drug was good and its blood levels were efficient for a prolonged period (at least 24 hours) after a single oral administration."( [Preclinical pharmacokinetics of pefloxacin].
Iudin, SM; Kashina, LB; Manuĭlov, KK; Strachunskiĭ, LS, 1994
)
0.57
" Pefloxacin is well absorbed from the gastrointestinal tract."( Pefloxacin clinical pharmacokinetics.
Bressolle, F; Galtier, M; Gonçalves, F; Gouby, A, 1994
)
2.64
" The relative bioavailability of pefloxacin after the antacid treatment was 44."( Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans.
Jaehde, U; Schunack, W; Sörgel, F; Stephan, U, 1994
)
0.78
" It was demonstrated that S/P is a function of the quotient of the rate of absorption and venous plasma drug concentration."( Kinetics of 4-fluoroquinolones permeation into saliva.
Antolic, G; Grabnar, I; Kozjek, F; Mrhar, A; Suturkova, LJ, 1999
)
0.3
" The results demonstrated that the carbopol/methyl cellulose mixture can be used as an in situ gelling vehicle to enhance the ocular bioavailability of pefloxacin mesylate."( Evaluation of carbopol-methyl cellulose based sustained-release ocular delivery system for pefloxacin mesylate using rabbit eye model.
Ali, A; Aqil, M; Sultana, Y; Zafar, S, 2006
)
0.75
"Therapeutic activity, pharmacokinetic and bioavailability on animals (inbred white mouse, rabbits) were evaluated for Ofloxacin-PhPO and Pefloxacin-genova in comparison with innovator products--Tarivid and Abaktal."( [Chemotherapy activity and pharmacokinetics of the fluoroquinolones generics Ofloxacin-PhPO and Pefloxacin-genova].
Bobrov, VI; Borisov, MM; Ptitsina, SN, 2007
)
0.76
" The absolute bioavailability (F%) obtained after IM administration was 71."( Concentration-time courses of pefloxacin in plasma and milk of lactating she-camels (Camelus dromedarius).
Abd El-Aty, AM; Chang, BJ; Goudah, A; Shah, SS; Shim, JH; Shin, HC,
)
0.42
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"h/ml along with relative bioavailability =91."( Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan.
Ali, SA; Gauhar, S; Naqvi, SB; Shoaib, MH, 2014
)
0.65
", solubility in an aqueous medium and lipophilic properties, which have an effect on the bioavailability of five selected fluoroquinolones."( Experimental and theoretical studies on the molecular properties of ciprofloxacin, norfloxacin, pefloxacin, sparfloxacin, and gatifloxacin in determining bioavailability.
Betlejewska-Kielak, K; Biernacka, J; Grudzień, M; Kłosińska-Szmurło, E; Mazurek, AP; Pluciński, FA, 2014
)
0.62
"Gold nanoparticles are useful candidate for drug delivery applications and are associated with enhancement in the bioavailability of coated drugs and/or therapeutic agent."( Synthesis of 4-(dimethylamino)pyridine propylthioacetate coated gold nanoparticles and their antibacterial and photophysical activity.
Ahmed, S; Anwar, A; Khalid, S; Khan, NA; Perveen, S; Shah, MR; Siddiqui, R, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Pefloxacin was applied per os or parenterally in the dosage of 800-1200 mg in the period from 5-9 days. The dosage regimen led to plasma concentrations of pefloxacIn and amikacin within their therapeutic range.

ExcerptRelevanceReference
" Symptoms can resolve when the pefloxacin dosage is reduced."( [Neurologic side effects of fluoroquinolones. Apropos of 9 cases concerning pefloxacin].
Andrejak, M; Debailleux, S; Hary, L; Moore, N; Schmit, JL; Tondriaux, A,
)
0.65
" The data consisted of 3 to 9 PF plasma levels per patient measured over 1 to 3 dosage intervals (total 113) according to four different limited (suboptimal) sampling 3-point protocols."( Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.
Alasia, M; Ballereau, M; Bruno, R; Cosson, V; Durand, A; Iliadis, MC; Lacarelle, B; Le Roux, Y; Mandema, JW; Montay, G, 1992
)
0.49
" leprae; temafloxacin and sparfloxacin were the most active, being fully bactericidal at all three dosage schedules."( Activities of various quinolone antibiotics against Mycobacterium leprae in infected mice.
Gelber, RH; Iranmanesh, A; Murray, L; Siu, P; Tsang, M, 1992
)
0.28
" Since the AUC in mice treated with ofloxacin 150 mg/kg daily is close to that in man treated with a clinically tolerated dose--600 mg daily--such a dosage may be only moderately effective against human tuberculosis."( Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments.
Grosset, J; Ji, B; Truffot-Pernot, C, 1991
)
0.64
" Dosage adjustments are required, particularly in severe renal failure and for the drugs almost exclusively excreted, in unchanged form, via the renal route."( Pharmacokinetics of quinolones in renal insufficiency.
Borsa-Lebas, F; Dhib, M; Fillastre, JP; Humbert, G; Leroy, A; Moulin, B, 1990
)
0.28
" Since no relationship between ofloxacin or pefloxacin kinetics and the usual liver function tests was found, recommended dosage regimens in cirrhotic patients have to be controlled by monitoring plasma drug levels during treatment."( Pharmacokinetics of fluoroquinolones in hepatic failure.
Gaillot, J; Montay, G, 1990
)
0.54
" Serum and milk samples were obtained simultaneously at two, four, six, nine, 12, and 24 hours after dosage administration."( Pharmacokinetics of three newer quinolones in pregnant and lactating women.
Aravantinos, D; Gazis, J; Giamarellou, H; Kolokythas, E; Petrikkos, G; Sfikakis, P, 1989
)
0.28
" Pefloxacin was applied per os or parenterally in the dosage of 800-1200 mg in the period from 5-9 days."( [Pefloxacin in the treatment of septicemia, purulent meningitis and salmonellosis].
Cengić, D; Dimitrijević, K; Dordević, D; Kaplan, M; Vranić, B, 1989
)
2.1
"05, student t-test) in mice treated twice daily with ciprofloxacin in dosage of 100 mg/kg/24 h, a concentration far beyond the therapeutic range."( The effect of ciprofloxacin and pefloxacin on bone marrow engraftment in the spleen of mice.
Barzilai, A; Lev, B; Rubinstein, E; Schwartz, E; Somekh, E, 1989
)
0.56
" This risk may depend on the dosing schedule and may be reduced by combined therapy."( Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis.
Auckenthaler, R; Michéa-Hamzehpour, M; Pechère, JC; Regamey, P, 1987
)
0.27
" A dosing schedule for the quinolones was proposed on the basis of pharmacokinetic parameters and microbiologic activity."( Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
Andrews, JM; Griggs, D; Wise, R,
)
0.13
" The dosage regimen led to plasma concentrations of pefloxacin and amikacin within their therapeutic range."( Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients.
Auzepy, P; Pezzano, M; Richard, C; Singlas, E; Sultan, E, 1988
)
0.85
" The dosage of 400 mg gave a mean serum concentration peak (11."( [Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics].
Benevent, D; Denis, F; Lagarde, C; Mounier, M, 1987
)
0.49
" Compared with non-burned subjects, burn patients exhibit a shorter elimination half-life, but modifications in dosage regimen are not required."( [Pharmacokinetics of pefloxacin in burn patients].
Baron, D; Drugeon, HB; Meignier, M; Montay, G; Potel, G; Touzé, MD, 1987
)
0.59
" With the present dosage regimen, CSF quickly attains therapeutic levels of pefloxacin."( Transfer kinetics of pefloxacin into cerebro-spinal fluid after one hour i.v. infusion of 400 mg in man.
Chazal, J; Djebbar, F; Dow, J; Frydman, AM; Gaillot, J; Janny, P; Woehrle, R, 1986
)
0.82
" Since renal excretion of the unchanged drug is less important, there is no need to modify the dosage in case of renal impairment."( [Pharmacokinetic behavior of pefloxacin in man].
Fourtillan, JB, 1986
)
0.56
" However, further clinical studies are required to determine the duration, dosage and in-vivo activity of the antibiotics."( In-vitro susceptibility of Pseudomonas pseudomallei isolated in Malaysia to some new cephalosporins and a quinolone.
Cheong, YM; Joseph, PG; Koay, AS, 1987
)
0.27
" This study suggests that a twice or possibly once daily dosage may be sufficient to treat systemic infections caused by susceptible pathogens."( Pharmacokinetics and tissue penetration of orally administered pefloxacin.
Andrews, JM; Ashby, JP; McLeod, A; Webberley, JM; Wise, R, 1987
)
0.51
"We reviewed, the structure, pharmacokinetic properties, mode of actions, antibacterial spectrum, therapeutic dosage and side effects of fluoroquinolones in this article."( [Fluoroquinolones].
Akalin, E; Baykal, M, 1987
)
0.27
" The rate of bacterial killing (delta log10 CFU/ml per h) did not change over a dosage range of 1 to 15 mg/kg per h (-0."( Evaluation of pefloxacin in experimental Escherichia coli meningitis.
Hackbarth, CJ; Sande, MA; Shibl, AM, 1986
)
0.63
" It is proposed that the decreased plasma clearance of pefloxacin in patients with cirrhosis is a result of decreased hepatic metabolism of the drug, and that the dosage should probably be modified in these patients."( Pefloxacin kinetics in cirrhosis.
Cunci, R; Danan, G; Erlinger, S; Montay, G, 1985
)
1.96
" The physician could choose between two different dosage schedules to use for surgical prophylaxis."( [Ultra-short and short surgical prophylaxis with pefloxacin].
Leo, P; Mangione, S, 1994
)
0.54
" To this purpose, 58 hospitalized patients with gynecologic malignancy and severe infectious complications were treated with intravenous pefloxacin at the dosage regimen of 400 mg every 12 hours."( Pefloxacin in the treatment of severe infections in gynecological cancer patients.
Colombo, M; Maggioni, A; Milani, R; Negri, L; Scalambrino, S, 1994
)
1.93
" Altered plasma pharmacokinetics in patients with liver insufficiency and in elderly patients are observed, so dosage adjustments are necessary."( Pefloxacin clinical pharmacokinetics.
Bressolle, F; Galtier, M; Gonçalves, F; Gouby, A, 1994
)
1.73
" Therefore, when pefloxacin treatment is indicated for cirrhotic patients, a reduced dosage and/or careful monitoring of pefloxacin serum levels should be recommended."( Grand mal seizures as a complication of treatment with pefloxacin in patients with cirrhosis. A report of three cases.
Bernard, B; Buffet, C; Cadranel, JF; Chapuis, L; Gargot, D; Hagege, H; Nordmann, P; Opolon, P; Valla, D, 1993
)
0.87
" Toxicity studies, including ophthalmological and histopathological investigations, identified a maximum non-toxic dosage of 400 micrograms."( Kinetics and tolerability of intravitreal pefloxacin in rabbits.
Bauchet, J; Cochereau-Massin, I; D'Hermies, F; Faurisson, F; Marrakchi-Benjaafar, S; Pocidalo, JJ; Vallois, JM, 1994
)
0.55
" Juvenile (4- to 5-week-old) NZW were orally dosed with ofloxacin or pefloxacin (300 mg/kg of body weight for 1 day) or with pefloxacin (300 mg/kg for 7 days)."( Cytofluorometric analysis of chondrotoxicity of fluoroquinolone antimicrobial agents.
Gaudin, C; Hayem, G; Kahn, MF; Levacher, M; Petit, PX; Pocidalo, JJ, 1994
)
0.52
" Nine days later, after a total dosage of pefloxacin of 800 mg, she was admitted to our hospital with a psychotic disorder."( An acute psychotic disorder caused by pefloxacin: a case report.
Berger, M; Hellwig, B; Hesslinger, B; Sester, U; Walden, J, 1996
)
0.83
" Pefloxacin was an effective and well tolerated treatment for respiratory tract infection and had the advantage of broad in-vitro antibacterial activity, twice daily dosing and sequential availability in an intravenous and oral formulation."( Evaluation of the efficacy of sequential intravenous-oral administration of pefloxacin in community-acquired lower respiratory tract infections in patients with underlying conditions.
Chan, CC; Ng, A; Poh, SC; Wang, YT; Yap, JC, 1995
)
1.43
" Nevertheless, duration of treatment (9 months) and occurrence of relapses despite a slowly tapering dosage schedule, expose patients to steroids side-effects."( [Pefloxacin as a first-line treatment for nephrotic syndrome in minimal glomerular lesions in the adult. Multicenter study of 32 patients].
Barka, A; Boulanger, H; Hauet, T; Landais, P; Nochy, D; Pruna, A, 1997
)
1.21
"The disposition kinetics and urinary excretion of pefloxacin after a single intravenous administration of 5 mg/kg were investigated in crossbred calves and an appropriate dosage regimen was calculated."( Disposition kinetics and urinary excretion of pefloxacin after intravenous injection in crossbred calves.
Deol, SS; Dumka, VK; Srivastava, AK, 2000
)
0.82
" These parameters may be used in evaluation of the drugs efficacy and for dosing corrections."( [The pharmacodynamics and pharmacokinetics of fluoroquinolones in the evaluation of antibacterial therapy regimens].
Smirnova, LB; Sokolova, VI, 2000
)
0.31
" The pharmacokinetics of pefloxacin and its active metabolite norfloxacin were investigated in chickens after a single oral administration of pefloxacin at a dosage of 10 mg/kg."( Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens.
Malik, JK; Pant, S; Rao, GS; Sastry, KV; Tripathi, HC, 2005
)
0.9
" The procedures were successfully applied to the determination of the drug in pharmaceutical dosage forms and humans serum samples with good recovery results."( Electroanalytical investigation and determination of pefloxacin in pharmaceuticals and serum at boron-doped diamond and glassy carbon electrodes.
Ozkan, SA; Topal, BD; Uslu, B, 2008
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
DNA synthesis inhibitorAny substance that inhibits the synthesis of DNA.
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
quinolone
N-arylpiperazine
N-alkylpiperazine
quinolone antibioticAn organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton.
fluoroquinolone antibioticAn organonitrogen heterocyclic antibiotic containing a quinolone (or quinolone-like) moiety and which have a fluorine atom attached to the central ring system.
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)134.00000.11007.190310.0000AID1443980; AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (41)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (282)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID428291Antimicrobial activity against Acinetobacter baumannii BM4652 expressing adeABC adeIJK double mutant isolated from patient with urinary tract infection by E test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID201082Antibacterial activity carried out in vitro against Staphylococcus aureus ATCC 292131989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
AID544853Antibacterial activity against Streptococcus pneumoniae R6 Tr6 harboring gyrA Ser81Phe mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID202111In vivo efficacy (orally) against Streptococcus pyogenes C-203 in mouse protection test1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID207383Inhibition of growth of Staphylococcus aureus (FDA207PJC-1) after incubation at 37 degree Centigrade1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Studies on prodrugs. 7. Synthesis and antimicrobial activity of 3-formylquinolone derivatives.
AID94278Antibacterial activity carried out in vitro against Klebsiella pneumoniae CMC 84-311989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
AID74853Antibacterial activity against five Gram-positive bacteria targeting topoisomerase II (DNA gyrase B GyrB)1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.
AID201953In vivo efficacy (orally) against Streptococcus pneumoniae SV-1 in mouse protection test1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID56591Days of the first positive reaction in depleted mice.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID428293Antimicrobial activity against Acinetobacter baumannii BM4651 expressing deltaadeIJK genes isolated from patient with urinary tract infection by E test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID207933In vitro antibacterial activity against Gram-positive, Staphylococcus aureus 209 P1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids.
AID540232Dose normalised AUC in monkey after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID203106Minimum inhibitory concentration (MIC) against gram positive bacteria Staphylococcus aureus H-228.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID497759Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Calu3 cells2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID544834Antibacterial activity against Streptococcus pneumoniae R6 Tr6 harboring gyrA Ser81Phe mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID96422In vitro minimum inhibitory concentration against growth of Klebsiella pneumoniae strain 396451984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Novel amino-substituted 3-quinolinecarboxylic acid antibacterial agents: synthesis and structure-activity relationships.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID205946Minimum inhibitory concentration (MIC) against gram positive bacteria Streptococcus pyogenes C-203.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID95889In vitro inhibition of growth of Klebsiella pneumoniae (PC-1602)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Studies on prodrugs. 7. Synthesis and antimicrobial activity of 3-formylquinolone derivatives.
AID237034Dissociation constant (pKa) was determined2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID206728Antibacterial activity was evaluated against Staphylococcus aureus2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
AID69782Antibacterial activity against Escherichia coli (H560)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID544868Antibacterial activity against Streptococcus pneumoniae U2A1414 harboring gyrA Glu85Lys parC Ser79Phe mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID497760Apparent permeability across apical to basolateral side in human Calu3 cells in presence of 3 uM PSC-833 P-gp inhibitor2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID450461Antibacterial activity against Escherichia coli after 24 hrs by twofold serial dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID544852Antibacterial activity against Streptococcus pneumoniae CP1000 by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID405463Antibacterial activity against Escherichia coli TOP10 in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID405460Antibacterial activity against Escherichia coli C600Rif containing pIP1206 plasmid in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID70704Minimum inhibitory concentration (MIC) against gram negative bacteria Escherichia coli H-560.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID530347Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID70571Compound was tested for inhibition of the gram-negative organism Escherichia coli vogel1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID544837Antibacterial activity against Streptococcus pneumoniae U2A1051 harboring gyrA Ser81Tyr mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID544862Antibacterial activity against Streptococcus pneumoniae U2A1693 harboring parC Asp83Asn mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID67532Minimum inhibitory concentration (MIC) against gram negative bacteria Enterobacter cloacae MA-2646.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID405467Antibacterial activity against Escherichia coli TOP10 containing pAT851 plasmid by Etest2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID544859Antibacterial activity against Streptococcus pneumoniae R6 Tr1 harboring parC Ser79Tyr mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID135327BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID96229Compound was tested for inhibition of the gram-negative organism Klebsiella pneumoniae MGH-21986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1646193Antibacterial activity against Escherichia coli incubated for 18 hrs by CLSI-based broth microdilution method2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Fluoroquinolones structural and medicinal developments (2013-2018): Where are we now?
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID163916Minimum inhibitory concentration (MIC) against gram negative bacteria Pseudomonas aeruginosa UI-18.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID544861Antibacterial activity against Streptococcus pneumoniae U2A1413 harboring parC Ser79Tyr mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID237037Dissociation constant (pKa) was determined2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID69597Antibacterial activity was evaluated against Escherichia coli2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
AID544866Antibacterial activity against Streptococcus pneumoniae U2A1056 harboring gyrA Ser81Tyr parC Asp83His mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID201575Antibacterial activity carried out in vitro against Streptococcus faecalis UCI 85-301989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
AID64565Antibacterial activity carried out in vitro against Escherichia coli MOR 84-201989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
AID405461Antibacterial activity against Escherichia coli TOP10 by Etest2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID163915In vivo efficacy (orally) against Pseudomonas aeruginosa in mouse protection test1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID1393809Antitubercular activity against Mycobacterium tuberculosis H37Rv by serial dilution assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Fluoroquinolone derivatives and their anti-tubercular activities.
AID203331In vitro inhibition of growth of Serratia marcescens (IAM1184)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Studies on prodrugs. 7. Synthesis and antimicrobial activity of 3-formylquinolone derivatives.
AID56593Number of mice which show positive phototoxic reaction in 5 mice1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID544833Antibacterial activity against Streptococcus pneumoniae CP1000 by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID497762Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Calu3 cells in presence of 3 uM PSC-833 P-gp inhibitor2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID70411In vitro for antibacterial activity against Gram-negative Escherichia coli NIJH JC-2.1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids.
AID163386In vitro inhibition of growth of Proteus vulgaris(OX-19)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Studies on prodrugs. 7. Synthesis and antimicrobial activity of 3-formylquinolone derivatives.
AID70751In vitro Inhibition of growth of Escherichia coli(KC-14)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Studies on prodrugs. 7. Synthesis and antimicrobial activity of 3-formylquinolone derivatives.
AID78707MIC at which cleaved DNA (linear) is observed at an intensity relative to oxolinic acid at 10 ug/mL by using Gyrase Induced DNA-Cleavage assay1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID430760Antiresorptive activity against 1,25-dihydroxyvitamin D3-stimulated osteoclast formation in Swiss Webster mouse bone marrow cells assessed as reduction of tartrate-resistant acid phosphatase activity after 7 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID163738Compound was tested for inhibition of the gram-negative organism Providencia rettgeri H17711986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID324752Antibacterial activity in Mycobacterium leprae infected mouse foot-pad model assessed as parasite killing at >300 mg/kg/day after 9 months2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID210022Antibacterial activity against Streptococcus pneumoniae (SV-1)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID428295Antimicrobial activity against Acinetobacter baumannii BM4579 expressing adeIJK genes with pAT807 isolated from patient with urinary tract infection by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID405465Antibacterial activity against Escherichia coli TOP10 containing pIP1206 plasmid in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID544831Antibacterial activity against Streptococcus pneumoniae CIP104485 by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID405457Antibacterial activity against Escherichia coli C600Rif in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID165223In vitro inhibition of growth of Pseudomonas aeruginosa(E-2)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Studies on prodrugs. 7. Synthesis and antimicrobial activity of 3-formylquinolone derivatives.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID544846Antibacterial activity against Streptococcus pneumoniae R6 Tr10 harboring gyrA Ser81Tyr parC Ser79Tyr mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID17991Bioavailability2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Search compounds with antimicrobial activity by applying molecular topology to selected quinolones.
AID544849Antibacterial activity against Streptococcus pneumoniae U2A1414 harboring gyrA Glu85Lys parC Ser79Phe mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID544860Antibacterial activity against Streptococcus pneumoniae U2A1053 harboring parC Ser79Phe mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID544856Antibacterial activity against Streptococcus pneumoniae U2A1051 harboring gyrA Ser81Tyr mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID122563Dose which has no effect to induce phototoxic reaction in 50% of mice by probit method.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID210196Compound was tested for inhibition of the gram-negative organism Streptococcus pneumoniae SV-11986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID209766Minimum inhibitory concentration against Streptococcus pyogenes Dig 72003Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7
Benzo[f]naphtyridones: a new family of topical antibacterial agents active on multi-resistant Gram-positive pathogens.
AID208893Compound was tested for inhibition of the gram-negative organism Streptococcus aureus H228.1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID544855Antibacterial activity against Streptococcus pneumoniae U2A1050 harboring gyrA Ser81Phe mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID133812Compound was evaluated for protective dose against the Escherichia coli vogel lethal infection following sc administration in mouse1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID324747Antibacterial activity against Mycobacterium leprae at 5 ug/mL after 11 to 18 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID544838Antibacterial activity against Streptococcus pneumoniae U2A1266 harboring gyrA Ser81Cys mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID497758Apparent permeability across basolateral to apical side in human Calu3 cells2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID133806Compound was evaluated for antibacterial activity in mice after peroral administration with 0.5 mL of Escherichia coli Vogel inoculum1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Novel amino-substituted 3-quinolinecarboxylic acid antibacterial agents: synthesis and structure-activity relationships.
AID1646194Antimicrobial activity against Pseudomonas aeruginosa ATCC 19429 incubated for 18 hrs by CLSI-based microbroth dilution method2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Fluoroquinolones structural and medicinal developments (2013-2018): Where are we now?
AID70705Minimum inhibitory concentration (MIC) against gram negative bacteria Escherichia coli Vogel.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID40783In vitro inhibition of growth of Bacillus subtilis (ATCC 6633)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Studies on prodrugs. 7. Synthesis and antimicrobial activity of 3-formylquinolone derivatives.
AID405454Antibacterial activity against Escherichia coli C600Rif by Etest2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID530349Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID133805Antibacterial activity in mice after intraperitoneal administration with 0.5 mL of Escherichia coli Vogel inoculum1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Novel amino-substituted 3-quinolinecarboxylic acid antibacterial agents: synthesis and structure-activity relationships.
AID67922Antibacterial activity evaluated against Enterococcus faecalis2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
AID78688Inhibitory concentration in supercoiling inhibition Escherichia coli DNA gyrase assay1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID1653117Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability2019European journal of medicinal chemistry, Mar-01, Volume: 165Quinolone hybrids and their anti-cancer activities: An overview.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID208894Compound was tested for inhibition of the gram-negative organism Streptococcus aureus UC-76.1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID450458Antibacterial activity against Bacillus subtilis after 24 hrs by twofold serial dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID206517Minimum inhibitory concentration against Quinolone sensitive Staphylococcus hominis IP8203 Strain.2001Bioorganic & medicinal chemistry letters, Apr-09, Volume: 11, Issue:7
Synthesis and biological evaluation of benzo[b]naphthyridones, a series of new topical antibacterial agents.
AID530348Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID544854Antibacterial activity against Streptococcus pneumoniae U2A1686 harboring gyrA Glu85Lys mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID64550Inhibition of growth of Escherichia coli (KC-14) upon oral administration in mice1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Studies on prodrugs. 7. Synthesis and antimicrobial activity of 3-formylquinolone derivatives.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID151531Antibacterial activity carried out in vitro against Pseudomonas aeruginosa K84-161989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
AID201952In vivo efficacy (s.c.) against Streptococcus pneumoniae SV-1 in mouse protection test1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID133815Compound was evaluated for protective dose against the Streptococcus aureus UC-76 lethal infection following sc administration in mouse1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID64390Antibacterial activity carried out in vitro against Enterobacter cloacae VHG 84-391989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
AID324745Inhibition of Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as inhibition of pBR322 DNA supercoiling2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID201085Antibacterial activity carried out in vitro against Staphylococcus aureus VGH 84-471989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
AID164231Antibacterial activity was evaluated against Pseudomonas aeruginosa2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID205558Minimum inhibitory concentration against Staphylococcus aureus AS51552003Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7
Benzo[f]naphtyridones: a new family of topical antibacterial agents active on multi-resistant Gram-positive pathogens.
AID133761Maximum tolerance dose was measured for phototoxic skin reaction by po administration1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID201072Activity was determined after peroral administration against Staphylococcus aureus Smith(MP) in mouse protection test1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
AID544832Antibacterial activity against Streptococcus pneumoniae R6 by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID67545Activity against Enterobacter aerogenes2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Search compounds with antimicrobial activity by applying molecular topology to selected quinolones.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID68850In vitro minimum inhibitory concentration against growth of Escherichia coli Vogel1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Novel amino-substituted 3-quinolinecarboxylic acid antibacterial agents: synthesis and structure-activity relationships.
AID405459Antibacterial activity against Escherichia coli C600Rif containing pIP1206 plasmid in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID244878In vitro antibacterial activity against Staphylococcus aureus Smith2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Synthesis and antibacterial activity of the 4-quinolone-3-carboxylic acid derivatives having a trifluoromethyl group as a novel N-1 substituent.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID405468Antibacterial activity against Escherichia coli TOP10 containing pAT851 in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID64564Antibacterial activity carried out in vitro against Escherichia coli ATCC 259221989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
AID65235In vivo efficacy in mouse protection test in Escherichia coli Vogel dose administered orally by gavage.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID540231Dose normalised AUC in dog after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID64544Activity was determined after peroral administration against Escherichia coli #311(MP) in mouse protection test1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
AID164709Compound was tested for inhibition of the gram-negative organism Pseudomonas aeruginosa UI-181986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID70570Compound was tested for inhibition of the gram-negative organism Escherichia coli H5601986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID544835Antibacterial activity against Streptococcus pneumoniae U2A1686 harboring gyrA Glu85Lys mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID540233Dose normalised AUC in human after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID411793Metabolic stability in human liver microsomes assessed as intrinsic clearance per mg of protein2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID74727Antibacterial activity against five Gram-negative bacteria1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.
AID544865Antibacterial activity against Streptococcus pneumoniae R6 Tr10 harboring gyrA Ser81Tyr parC Ser79Tyr mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID207175Antibacterial activity against Staphylococcus aureus (H228)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID117861Dose required to induce phototoxic reaction in 50% of mice by probit method at different dosage forms.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID544867Antibacterial activity against Streptococcus pneumoniae U2A1060 harboring gyrA Ser81Phe parC Asp83His mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID64561Antibacterial activity carried out in vitro against Escherichia coli #311(MP)1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID544848Antibacterial activity against Streptococcus pneumoniae U2A1060 harboring gyrA Ser81Phe parC Asp83His mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID161378Minimum inhibitory concentration (MIC) against gram negative bacteria Prot. rettgeri M-1771.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID450460Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by twofold serial dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID162778In vitro minimum inhibitory concentration against growth of Pseudomonas aeruginosa MGH-21984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Novel amino-substituted 3-quinolinecarboxylic acid antibacterial agents: synthesis and structure-activity relationships.
AID205945Minimum inhibitory concentration (MIC) against gram positive bacteria Streptococcus pneumoniae SV-1.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID201084Antibacterial activity carried out in vitro against Staphylococcus aureus Smith(MP)1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1546202Antimicrobial activity against Pseudomonas aeruginosa assessed as zone of inhibition at 5 mg/ml2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID405456Antibacterial activity against Escherichia coli C600Rif in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID209087Compound was tested for inhibition of the gram-negative organism Streptococcus faecalis MGH-21986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1653121Cytotoxicity against human HL60 cells assessed as reduction in cell viability2019European journal of medicinal chemistry, Mar-01, Volume: 165Quinolone hybrids and their anti-cancer activities: An overview.
AID324746Effect on Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as enhancement of supercoiled pBR322 DNA cleavage2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID65234In vivo efficacy in mouse protection test in Escherichia coli Vogel administered by subcutaneous injection.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID244930In vitro antibacterial activity against Streptococcus pneumoniae type III2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Synthesis and antibacterial activity of the 4-quinolone-3-carboxylic acid derivatives having a trifluoromethyl group as a novel N-1 substituent.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID544841Antibacterial activity against Streptococcus pneumoniae U2A1053 harboring parC Ser79Phe mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID95531Minimum inhibitory concentration (MIC) against gram negative bacteria Klebsiella pneumoniae MGH-2.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID133810Compound was evaluated for protective dose against the Escherichia coli vogel lethal infection following peroral administration in mouse1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID205683Minimum inhibitory concentration against Staphylococcus aureus RN42202003Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7
Benzo[f]naphtyridones: a new family of topical antibacterial agents active on multi-resistant Gram-positive pathogens.
AID164385Antibacterial activity against Pseudomonas aeruginosa (UI-18)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID133817Compound was evaluated for protective dose against the Streptococcus pneumoniae SV-1 lethal infection following po administration1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID405466Antibacterial activity against Escherichia coli TOP10 containing pIP1206 plasmid in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID450459Antibacterial activity against Serratia marcescens after 24 hrs by twofold serial dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID544847Antibacterial activity against Streptococcus pneumoniae U2A1056 harboring gyrA Ser81Tyr parC Asp83His mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID244871In vitro antibacterial activity against Escherichia coli NIHJ JC-22005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Synthesis and antibacterial activity of the 4-quinolone-3-carboxylic acid derivatives having a trifluoromethyl group as a novel N-1 substituent.
AID64545Activity was determined after subcutaneous administration against Escherichia coli #311(MP) in mouse protection test1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID202110In vivo efficacy (s.c.) against Streptococcus pyogenes C-203 in mouse protection test1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID544864Antibacterial activity against Streptococcus pneumoniae U2A1681 harboring parC Ser79Tyr Asp83Ala mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID544844Antibacterial activity against Streptococcus pneumoniae U2A1411 harboring parC Asp83Gly mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID207705Minimum inhibitory concentration against Quinolone Resistant Staphylococcus aureus LF11C128B Strain.2001Bioorganic & medicinal chemistry letters, Apr-09, Volume: 11, Issue:7
Synthesis and biological evaluation of benzo[b]naphthyridones, a series of new topical antibacterial agents.
AID540230Dose normalised AUC in rat after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID20922Compound was evaluated for aqueous solubility at pH 7.21992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID497757Apparent permeability across apical to basolateral side in human Calu3 cells2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID1546204Antimicrobial activity against Klebsiella pneumoniae assessed as zone of inhibition at 5 mg/ml2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID544863Antibacterial activity against Streptococcus pneumoniae U2A1411 harboring parC Asp83Gly mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID201073Activity was determined after subcutaneous administration against Staphylococcus aureus Smith(MP) in mouse protection test1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
AID544858Antibacterial activity against Streptococcus pneumoniae H548 clinical isolate harboring gyrA Ser81Phe mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID428294Antimicrobial activity against Acinetobacter baumannii BM4652 expressing adeIJK genes with pAT807 isolated from patient with urinary tract infection by E test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID428292Antimicrobial activity against Acinetobacter baumannii BM4579 expressing deltaadeIJK genes isolated from patient with urinary tract infection by E test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID207212In vitro minimum inhibitory concentration against growth of Staphylococcus aureus Smith1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Novel amino-substituted 3-quinolinecarboxylic acid antibacterial agents: synthesis and structure-activity relationships.
AID237458Partition coefficient (logD7.4)2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID70860Compound was tested for inhibition of the gram-negative organism Escherichia cloacae HA 26461986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID428290Antimicrobial activity against Acinetobacter baumannii BM4454 isolated from patient with urinary tract infection by E test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID78709Inhibition of DNA gyrase of Escherichia coli H560 cells1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID497761Apparent permeability across basolateral to apical side in human Calu3 cells in presence of 3 uM PSC-833 P-gp inhibitor2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID530346Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID405469Antibacterial activity against Escherichia coli TOP10 containing pAT851 in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID544850Antibacterial activity against Streptococcus pneumoniae CIP104485 by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID544843Antibacterial activity against Streptococcus pneumoniae U2A1693 harboring parC Asp83Asn mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID544851Antibacterial activity against Streptococcus pneumoniae R6 by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID405464Antibacterial activity against Escherichia coli TOP10 containing pIP1206 plasmid by Etest2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID95885Antibacterial activity against Klebsiella pneumonia (MGH-2)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID405458Antibacterial activity against Escherichia coli C600Rif containing pIP1206 plasmid by Etest2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID544840Antibacterial activity against Streptococcus pneumoniae R6 Tr1 harboring parC Ser79Tyr mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID405462Antibacterial activity against Escherichia coli TOP10 in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID209302Compound was tested for inhibition of the gram-negative organism Streptococcus pyogenes C203.1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID530345Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID164550In vitro antibacterial activity against Gram-negative Pseudomonas aeruginosa V-1.1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids.
AID544857Antibacterial activity against Streptococcus pneumoniae U2A1266 harboring gyrA Ser81Cys mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID497756Distribution coefficient, log D of the compound2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID163914In vivo efficacy (s.c.) against Pseudomonas aeruginosa in mouse protection test1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID1646195Antimicrobial activity against Staphylococcus aureus ATCC 25923 incubated for 18 hrs by CLSI-based microbroth dilution method2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Fluoroquinolones structural and medicinal developments (2013-2018): Where are we now?
AID450457Antibacterial activity against Staphylococcus aureus after 24 hrs by twofold serial dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID51918Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity)1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.
AID133813Compound was evaluated for protective dose against the Streptococcus aureus UC-76 lethal infection following po administration in mouse1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID133807Compound was evaluated for protective dose against Streptococcus pneumoniae SV-1 lethal infection following sc administration1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1546205Antimicrobial activity against Escherichia coli assessed as zone of inhibition at 5 mg/ml2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID244897In vitro antibacterial activity against Pseudomonas aeruginosa IID12102005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Synthesis and antibacterial activity of the 4-quinolone-3-carboxylic acid derivatives having a trifluoromethyl group as a novel N-1 substituent.
AID530350Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID201083Antibacterial activity carried out in vitro against Staphylococcus aureus K82-261989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
AID205944Minimum inhibitory concentration (MIC) against gram positive bacteria Streptococcus faecalis MGH-2.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID544836Antibacterial activity against Streptococcus pneumoniae U2A1050 harboring gyrA Ser81Phe mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID498872Antimicrobial activity against Acinetobacter baumannii B9 containing carbapenemase blaOXA-23 gene assessed as growth inhibition by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.
AID544845Antibacterial activity against Streptococcus pneumoniae U2A1681 harboring parC Ser79Tyr Asp83Ala mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID237457Partition coefficient (logD2.0)2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID201607Antibacterial activity carried out in vitro against Serratia marcescens MOR 84-411989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
AID544839Antibacterial activity against Streptococcus pneumoniae H548 clinical isolate harboring gyrA Ser81Phe mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID69784Antibacterial activity against Escherichia coli (vogel)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID203107Minimum inhibitory concentration (MIC) against gram positive bacteria Staphylococcus aureus UC-76.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
AID1546203Antimicrobial activity against Staphylococcus aureus assessed as zone of inhibition at 5 mg/ml2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID1653202Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability2019European journal of medicinal chemistry, Mar-01, Volume: 165Quinolone hybrids and their anti-cancer activities: An overview.
AID544842Antibacterial activity against Streptococcus pneumoniae U2A1413 harboring parC Ser79Tyr mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (851)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990274 (32.20)18.7374
1990's396 (46.53)18.2507
2000's113 (13.28)29.6817
2010's51 (5.99)24.3611
2020's17 (2.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 57.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index57.24 (24.57)
Research Supply Index6.98 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index97.95 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (57.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials135 (14.44%)5.53%
Reviews44 (4.71%)6.00%
Case Studies79 (8.45%)4.05%
Observational0 (0.00%)0.25%
Other677 (72.41%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]